Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]

  • Awaiting development
  • GID-TA11882
  • Expected publication date: TBC

34430-Imsamotide-Etimumotide-Pembrolizumab-for-Melanoma-V1.0-SEP2025-NON-CONF.pdf